

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

=====

FORM 8-K/A  
(AMENDMENT NO. 1)

=====

CURRENT REPORT

=====

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

AUGUST 2, 2001

-----  
Date of report (Date of earliest event reported)

INTEGRA LIFESCIENCES HOLDINGS CORPORATION  
(exact name of registrant as specified in its charter)

DELAWARE

51-0317849

-----  
(State or other jurisdiction of Commission (I.R.S. Employer Identification  
incorporation or organization) File Number Number)

311 ENTERPRISE DRIVE, PLAINSBORO, NEW JERSEY 08536

-----  
(Address of Principal Executive Offices) (Zip Code)

(609) 275-0500

-----  
(Registrant's telephone number, including area code)

NOT APPLICABLE

-----  
(Former name or former address, if changed since last report.)

=====

The undersigned Registrant hereby amends Item 5 and the financial page of Exhibit 99.1 of its Current Report on Form 8-K dated August 2, 2001.

ITEM 5. OTHER EVENTS.

On August 2, 2001 Integra LifeSciences Holdings Corporation (Nasdaq: IART) (the "Company") reported its financial results for the second quarter of 2001 in a press release. A copy of the Company's press release has been filed as an exhibit to a Current Report on Form 8-K filed on August 2, 2001.

The press release contained an error in the calculation of basic earnings per share for the three-month period ended June 30, 2001 because it did not include the non-cash dividends associated with the Company's Series B Preferred Stock during that portion of the period in which the Series B Preferred Stock was outstanding. The Series B Preferred Stock was converted into 2,617,800 common shares on June 26, 2001.

The basic earnings per share for the three-month period ended June 30, 2001 was incorrectly reported as \$0.13. The correct basic earnings per share for such period is \$0.12, which includes the effect of the non-cash dividends. All other earnings per share calculations in the press release were calculated and reported correctly.

A revised copy of the financial page of the Company's original press release has been filed as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(a) and (b) None.

The following document is furnished as an Exhibit to this Current Report on Form 8-K pursuant to Item 601 of Regulation S-K:

99.1 Revised copy of the financial page to the Press Release, dated August 2, 2001.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES  
HOLDINGS CORPORATION

By: JOHN B. HENNEMAN III

-----  
Name: John B. Henneman III  
Title: Senior Vice President,  
Chief Administrative Officer  
and Secretary

Date: August 6, 2001

EXHIBIT INDEX

EXHIBIT NO.	DOCUMENT DESCRIPTION
99.1	Revised copy of the financial page to the Press Release, dated August 2, 2001.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION  
CONSOLIDATED FINANCIAL RESULTS  
(In thousands, except per share data)  
(UNAUDITED)

Statement of Operations Data:

	Three Month Period Ended June 30		Six Month Period Ended June 30	
	2001	2000	2001	2000
	-----	-----	-----	-----
Product sales	\$21,385	\$15,827	\$41,669	\$29,159
Other revenue	1,535	1,259	2,935	2,458
	-----	-----	-----	-----
Total revenue	22,920	17,086	44,604	31,617
Cost of product sales	8,310	7,212	16,904	13,899
Research and development	1,837	2,004	3,910	3,894
Selling and marketing	5,269	3,904	10,020	6,853
General and administrative	3,319	3,884	6,523	7,631
Amortization	729	670	1,409	1,150
	-----	-----	-----	-----
Total costs and expenses	19,464	17,674	38,766	33,427
Operating income (loss)	3,456	(588)	5,838	(1,810)
Gain on disposition of product line	--	1,031	--	1,146
Other expense, net	(265)	(170)	(405)	(36)
	-----	-----	-----	-----
Income (loss) before income taxes	3,191	273	5,433	(700)
Provision for income taxes	429	161	675	223
	-----	-----	-----	-----
Income (loss) before accounting change	2,762	112	4,758	(923)
Cumulative effect of accounting change	--	--	--	(470)
	-----	-----	-----	-----
Net income (loss)	\$ 2,762	\$ 112	\$ 4,758	\$(1,393)
Earnings (loss) per share				
Basic	\$ 0.12	\$ (0.02)	\$ 0.20	\$ (0.36)
Diluted	\$ 0.10	\$ (0.02)	\$ 0.18	\$ (0.36)
Weighted average Common shares outstanding:				
Basic	20,245	17,341	19,931	17,282
Diluted	25,049	17,341	22,211	17,282

Balance Sheet Data:

	30-JUN 2001	31-DEC 2000
	-----	-----
Cash, cash equivalents & investments	\$11,655	\$15,138
Working capital	28,299	25,177
Total assets	94,193	86,514
Total debt	9,703	13,630
Total stockholders' equity	62,522	53,781